<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2006</study_start_year><condition>Colorectal Cancer</condition><condition>Colorectal Neoplasms</condition><disease>Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2033619</full_dataset_link><location>Israel</location><study_start_month>10</study_start_month><keyword>Leucovorin</keyword><keyword>Colorectal cancer, DAVANAT, colon cancer, 5-FU</keyword><keyword>Fluorouracil</keyword><keyword>Bevacizumab</keyword><repository>ECRIN MDR</repository><study_status>Withdrawn</study_status></additional><is_claimable>false</is_claimable><name>A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer</name><description>The purpose of this clinical trial is to determine whether the combination of 5-fluorouracil (5-FU) plus a DAVANAT (carbohydrate polymer) along with Avastin and Leucovorin (LV) is beneficial in treating colorectal cancer in patients unable to tolerate intensive chemotherapy.</description><dates><creation>2006-10-15</creation></dates><accession>2033619</accession><cross_references><ClinicalTrials___gov>NCT00388700</ClinicalTrials___gov></cross_references></HashMap>